Form 4 for REGN Regeneron Pharmaceuticals
Accepted 2026-09-03 16:50:59 ET · period of report 2026-09-02 · accession 0001663758-26-000002 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| MT | 2026-09-03 16:50 | 2026-09-02+ | REGN | McCourt Marion | EVP Commercial | S - Sale | $853.56 | -2,346 | 12.0K | -16% | -$2.00M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-09-02 | S | D | 1,215 | $850.00 | 13,134 | D | — | — | (F1) Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 17, 2026. |
| 2 | Common | Common Stock | 2026-09-03 | S | D | 1,131 | $857.39 | 12,003 | D | — | — | (F1) Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 17, 2026. |